Register
Forgot your password?

The possibility of using galectin-3 for predictingthe outcomes of myocardial infarction

Authors: Fedorova N.V. 1, Kashtalap V.V. 1,2, 2, Kagan E.S. 3, Hryachkova O.N. 1, Barbarash O.L. 1,2, 2

Company: 1 Research Institute for Complex Issues of Cardiovascular Diseases, Sosnovyy bul'var, 6, Kemerovo, 650002, Russian Federation;
2 Kemerovo State Medical University of Ministry of Health of the Russian Federation, 22A, ulitsa Voroshilova, Kemerovo, 650029, Russian Federation;
3Kemerovo State University, ulitsa Krasnaya, 6, Kemerovo, 650000, Russian Federation

For correspondence:  Sign in or register.

Type:  Ischemic heart disease


DOI: https://doi.org/10.24022/1997-3187-2018-12-1-11-21

For citation: Fedorova N.V., Kashtalap V.V., Kagan E.S., Hryachkova O.N., Barbarash O.L. The possibility of using galectin-3 for predicting the outcomes of myocardial infarction. Creative Cardiology (Kreativnaya Kardiologiya). 2018; 12 (1): 11–21 (in Russ.). DOI: 10.24022/1997-3187-2018-12-1-11-21.

Received / Accepted:  17.07.2017/24.07.2017

Keywords: myocardial infarction prognosis galectin-3

Download
Full text:  

 

Abstract

Introduction. Myocardial infarction (MI) is one of the most common cause of disability and mortality in developed countries. Prediction of adverse outcomes in both early and long periods of MI using biomarkers is an urgent task of modern medicine.

Objective. To evaluate the predictive role of galectin-3 in patients with ST-segment elevation MI.

Material and methods. The study included 259 patients during first 24 hours of ST-segment elevation MI. All patients underwent standard laboratory and instrumental examination. Coronary angiography with percutaneous coronary intervention was performed on most patients (98,5%). Galectin-3 was determined by enzyme-linked immunosorbent assay on the first and 10–14th day of the disease. Long-term follow-up period was 12,4±1,1 months. The “end points” were as follows: death from any cause, recurrent MI, insult or transient ischemic attack, hospitalization for angina or heart failure. The compliance to medical treatment was analyzed.

Results. Adverse outcomes at long-term follow-up were registered in 72 (34%) patients. Recurrent MI and hospitalization for unstable angina were the most frequent adverse events. Galectin-3 estimated on the 10–14th days of MI, a high SYNTAX score and low compliance had a high prognostic significance to assess the risk of adverse events during one year after MI. The combination of these factors allows to calculate the probability of adverse events. The sensitivity of this prognostic model was 71.4%, while the specificity of the model – 63.2%, the area under the ROC curve was 0.741 (р=0.0001).

Conclusion. Galectin-3, estimated on the 10–14th day of the MI, can improve approaches to the risk evaluation in the of adverse events during one year after MI.

References

  1. Nikitina S.Yu. Healthcare in Russian. Moscow;2015 (in Russ.)

  2. The top 10 causes of death. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index.html .

  3. Artamonova G.V., Kheraskov V.Yu., Kryuch-kov D.V., Barbarash L.S. А systemic approach tomediсаl care for patients with myocardial infarc-tion – “kemerovo model”. Complex Issues ofCardiovascular Diseases (Kompleksnye Problemy Serdechno-Sosudistykh Zabolevaniy).2013; (1):52–9.  DOI: 10.17802/2306-1278-2013-1-52-59.

  4. Mandelzweig L., Battler A., Boyko V. et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur. Heart J. 2006; 27: 2285–93.

  5. Tsai T.H., Chua S., Hussein H. et al. Outcomes of patients with killip class III acute myocardial infarction after primary percutaneous coronary intervention. Crit. Care Med. 2011; 39: 436–42.

  6. Littnerova S., Kala P., Jarkovsky J. et al. GRACE score among six risk scoring Systems (CADILLAC, PAMI, TIMI, Dynamic TIMI, ZWOLLE) demonstrated the best predictive value for prediction of long-term mortality in patients with ST-elevation myocardial infarction. PloS One. 2015; 10 (4). DOI: 10.1371/journal.Pone.0123215.

  7. Barbarash O.L., Zykov M.V., Kashtalap V.V. et al.Prognostic value of various markers of inflamma-tion in myocardial infarction with ST-segment ele-vation. Cardiology (Kardiologiya).2011; 3: 24–30(in Russ.).

  8. Zykov M.V., Barbarash O.L., Zykova D.S. et al.Comparative characteristics of hospital mortalityprediction scales in patients with myocardial infarc-tion. Russian Cardiology Journal (RossiyskiyKardiologicheskiy Zhurnal).2012; 1: 11–6 (in Russ.).

  9. Bobrovskaya E.E., Burova N.N., Kon V.E.Predictors of complicated course and unfavorableprognosis in patients with myocardial infarction.Arterial Hypertension (Arterial'naya Gipertenziya).2009; 15 (5): 539–42 (in Russ.)

  10. Nechesova T.A., Korobko I.Yu., Kuznetsova N.I.Remodeling of left ventricular: pathogenesis andmethods of assessment. Medical News (MeditsinskieNovosti).2008; 11: 7–13 (in Russ.)

  11. Mallick A., Januzzi J.L. Biomarkers in acute heart failure. Rev. Esp. Cardiol. 2015; 68: 514–25.

  12. Grandin E.W., Jarolim P., Murphy S.A. et al. Galectin-3 and the development of HF after Acute Coronary Syndrome: pilot experience from PROVE IT-TIMI 22. Clin. Chem. 2011; 58 (1): 1–7.

  13. George M., Shanmugam E., Srivatsan V. et al. Value of pentraxin-3 and galectin-3 in acute coronary syndrome: a short-term prospective cohort study. Ther. Adv. Cardiovasc. Dis. 2015; 9 (5): 275–84.

  14. Drapkina O.M., Deeva T.A. Galectin-3 – biomarkerof fibrosis in patients with metabolic syndrome.Russian Cardiology Journal (Rossiyskiy Kardiolo-gicheskiy Zhurnal).2015; 9 (125): 96–102 (in Russ.).

  15. De Boer R.A., Yu L., van Veldhuisen D.J. Galectin-3 in cardiac remodeling and heart failure. Curr. Heart Fail. Rep. 2010; 7 (1): 1–8.

  16. Arias T., Petrov A., Chen J. et al. Labeling galectin-3 for the assessment of myocardial infarction in rats. EJNMMI Res. 2014; 4 (1): 75.

  17. Fedorova N.V., Kashtalap V.V., Hryachkova O.N.,Barbarash O.L. Galectin-3 – prospective biomark-er of risk stratification in patients with ST-segmentelevation myocardial infarction. Ateroskleroz. 2015;11 (4): 49–55 (in Russ.).

  18. National recommendations for diagnosis and treat-ment of patients with ST-segment elevationmyocardial infarction. Cardiovascular Therapy andPrevention (Kardiovaskulyarnaya Terapiya iProfilaktika).2007; 6 (8): 415–500 (in Russ.).

  19. Vasil'eva O.A., Yakusheva V.D., Ryazantseva N.V.,Novitskiy V.V. Use Galectin-3 in laboratory diag-nostics. Clinical Laboratory Council of Physicians(Kliniko-Laboratornyy Konsilium).2011; 2: 12–8(in Russ.).

  20. Bosnjak I., Selthofer-Relatic K., Vcˇev A. Prognostic value of galectin-3 in patients with heart failure. Dis. Markers. 2015. DOI: 10.1155/2015/690205.

  21. Van der Velde A.R., Gullestad L., Ueland T. et al. Prognostic value of changes in Galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ. Heart Fail. 2013; 6: 219–26.

  22. Van Kimmenade R.R., Januzzi J.L., Ellinor P.T. et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J. Am. Coll. Cardiol. 2006; 48 (6): 1217–24.

  23. Ho J.E., Liu C., Lyass A. et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012; 60 (14): 1249–56.

  24. Jagodzinski A., Havulinna A.S., Appelbaum S. et al. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the populationbased FINRISK 1997 cohort. Int. J. Cardiol. 2015; 192: 33–9.

  25. De Boer R.A., Van Veldhuisen D.J., Gansevoort R.T. et al. The fibrosis marker galectin-3 and outcome in general population. J. Intern. Med. 2012; 272: 55–64.

  26. Tsai T.H., Sung P.H., Chang L.T. et al. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J. Atheroscler. Thromb. 2012; 19: 1073–82.

  27. Sharma U., Rhaleb N.E., Pokharel S. et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser- Asp-Lys-Pro in hypertension-induced target organ damage. Am. J. Physiol. Heart. Circ. Physiol. 2008; 294 (3): 1226–32.

  28. Lisowska A., Knapp M., Tyci_ska A. et al. Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016; 246: 309–17.

About Authors

  • Fedorova Natal'ya Vasil'evna, Researcher, orcid.org/0000-0002-3841-8539;

  • Kashtalap Vasiliy Vasil'evich, Dr Med. Sc., Head of Laboratory, Associate Professor, orcid.org/0000-0003-3729-616X;

  • Kagan Elena Sergeevna, Cand. Tech. Sc., Associate Professor, Chief of Chair, orcid.org/0000-0002-8470-961X;

  • Khryachkova Oksana Nikolaevna, Junior Researcher, orcid.org/0000-0002-6620-5960;

  • Barbarash Ol'ga Leonidovna, Corresponding Member of Russian Academy of Sciences, Dr Med. Sc., Professor, Director, orcid.org/0000-0002-4642-3610

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Sort by